| Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. | |
| | |
MedLine Citation:
|
PMID: 12029557 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this prospective study was to evaluate yttrium-90 glass microsphere treatment of unresectable liver metastases by fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG PET), and to compare the effectiveness of [18F]FDG PET for this purpose with that of computed tomography (CT) or magnetic resonance imaging (MRI) and determination of the serum carcinoembryonic antigen (CEA) level. Thirteen hepatic lobes from eight consecutive patients with colorectal cancer referred for 90Y-glass microsphere treatment of unresectable liver metastases who underwent both baseline (pretreatment) and 3-month posttreatment PET were studied. All patients also had correlative pre- and posttreatment CT or MRI for evaluation of the anatomic response and serum CEA determination for assessment of the total tumor load, as well as pretreatment hepatic intra-arterial technetium-99m macroaggregated albumin scan for lung shunting evaluation and hepatic arteriography for assessment of vascular anatomy and treatment. 90Y-glass microspheres were infused via an intra-arterial catheter under low pressure. Dedicated whole-body PET scans were analyzed visually and compared by lesion and by lobe with CT or MRI. A metabolic response after 90Y treatment to single or both hepatic lobes, assessed by PET, was present in a significantly higher proportion of the lobes than was an anatomic response, evaluated by CT or MRI (12 vs 2 lobes respectively, P<0.0002). Posttreatment PET showed no, stable, progressive, and new extrahepatic metastases in two, three, one, and two patients respectively. Following treatment, serum CEA decreased significantly, correlating with PET but not with CT or MRI. Thus, the study demonstrated a significant difference between the metabolic and the anatomic response after 90Y-glass microsphere treatment for unresectable liver metastases in colorectal cancer. PET appears to be an accurate indicator of treatment response. |
| | |
Authors:
|
Ching-yee Oliver Wong; Riad Salem; Subha Raman; Vanessa L Gates; Howard J Dworkin |
Related Documents
:
|
19190917 - Whole-body mri at 1.5 t and 3 t compared with fdg-pet-ct for the detection of tumour re... 19415387 - Clinical and pathological factors related to 18f-fdg-pet positivity in the diagnosis of... 18037877 - Extensive tubercular neck lymphadenopathy in a man with early-stage tongue cancer. 10742677 - Clinical utility of fdg-pet in detecting head and neck tumors. a comparison of diagnost... 7335157 - The syndrome of absence of the septum pellucidum with porencephalies and other developm... 1944067 - Tuberous sclerosis: relationships between topographic mapping of eeg, veps and mri find... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article Date: 2002-03-29 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 29 ISSN: 1619-7070 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2002 Jun |
Date Detail:
|
Created Date: 2002-05-24 Completed Date: 2003-01-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 815-20 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, William Beaumont Hospital, 3601 W. Thirteen Mile Road, Royal Oak, MI 48073-6769, USA. owong@beaumont.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Carcinoembryonic Antigen / analysis Colorectal Neoplasms / pathology* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Liver Neoplasms / diagnosis*, radionuclide imaging, radiotherapy, secondary* Lung Neoplasms / diagnosis, secondary Lymphatic Metastasis Magnetic Resonance Imaging Male Microspheres Middle Aged Prospective Studies Radiopharmaceuticals / diagnostic use, therapeutic use Severity of Illness Index Tomography, X-Ray Computed Treatment Outcome Tumor Markers, Biological / analysis Yttrium Radioisotopes / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Carcinoembryonic Antigen; 0/Radiopharmaceuticals; 0/Tumor Markers, Biological; 0/Yttrium Radioisotopes; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer pa...
Next Document: Copper-67 as a therapeutic nuclide for radioimmunotherapy.